The glutamatergic system and Alzheimer's disease: therapeutic implications.

abstract：BACKGROUND:No head-to-head clinical trials have been published comparing guanfacine extended release (GXR) and atomoxetine (ATX): two nonstimulants approved for the treatment of attention-deficit/hyperactivity disorder (ADHD). However, other study designs or methods could be used to indirectly compare these two medicat...

journal_title：CNS drugs

authors： Sikirica V,Findling RL,Signorovitch J,Erder MH,Dammerman R,Hodgkins P,Lu M,Xie J,Wu EQ

更新日期：2013-11-01 00:00:00

abstract：:Major depressive disorder (MDD) is a chronic, recurrent mental disease that causes serious disability. Because currently available antidepressants have limited efficacy with respect to response and remission in patients with MDD, clinicians must choose the best available treatment interventions for patients who do not...

journal_title：CNS drugs

authors： Pae CU,Patkar AA

更新日期：2013-05-01 00:00:00

abstract：:It is difficult to determine the relative efficacy of atypical antipsychotics for the treatment of schizophrenia, based on the available literature. The purpose of this article is to review and compare the efficacy of two atypical antipsychotics: olanzapine and ziprasidone.This review focused on randomised trials in w...

journal_title：CNS drugs

authors： Matza LS,Baker TM,Revicki DA

更新日期：2005-01-01 00:00:00

abstract：:Neuropathic pain is a persistent pain condition that develops secondary to nerve injury. The two most common types of peripheral neuropathic pain are post-herpetic neuralgia (PHN) and painful diabetic neuropathy (PDN). Amitriptyline, nortriptyline, desipramine and imipramine are TCAs that have been shown to be effecti...

journal_title：CNS drugs

authors： Zin CS,Nissen LM,Smith MT,O'Callaghan JP,Moore BJ

更新日期：2008-01-01 00:00:00

abstract：:Multiple stimulant and non-stimulant medications are approved for the treatment of attention-deficit/hyperactivity disorder (ADHD), one of the most prevalent childhood neurodevelopmental disorders. Choosing among the available agents and determining the most effective ADHD medication for a given child can be a time-co...

journal_title：CNS drugs

authors： Elsayed NA,Yamamoto KM,Froehlich TE

更新日期：2020-04-01 00:00:00

abstract：:Attention-deficit/hyperactivity disorder, or ADHD, is the most frequently occurring neurobiological disorder in childhood and is defined by symptoms of inattention and/or hyperactivity and impulsivity that are excessive when compared with other individuals at the same developmental level. ADHD can be successfully trea...

journal_title：CNS drugs

authors： Childress AC,Sallee FR

更新日期：2014-02-01 00:00:00

abstract：:Numerous in vitro and in vivo experimental animal studies have demonstrated that gangliosides, particularly GMI ganglioside (siagoside), may stimulate or accelerate the repair of peripheral and central nervous system neurons after various types of damage. Clinical studies of GMl in peripheral neuropathies and stroke, ...

journal_title：CNS drugs

authors： Schneider JS

更新日期：1994-03-01 00:00:00

abstract：:The eating disorders anorexia nervosa and bulimia nervosa present with comorbidity in a number of important areas, including depression, bipolar disorder, anxiety disorders (obsessive-compulsive disorder, panic disorder, social anxiety disorder and other phobias, and post-traumatic stress disorder) and substance abuse...

journal_title：CNS drugs

authors： Woodside BD,Staab R

更新日期：2006-01-01 00:00:00

abstract：:Multiple sclerosis (MS) is a demyelinating disease of the central nervous system that is pathologically characterized by inflammatory demyelination and neurodegeneration. Axonal damage, along with neuronal loss, occurs from disease onset and may lead to progressive and permanent disability. In contrast with the inflam...

journal_title：CNS drugs

authors： Maghzi AH,Minagar A,Waubant E

更新日期：2013-10-01 00:00:00

abstract：BACKGROUND:A recent large database analysis raised concerns of potential acute kidney injury (AKI) risk associated with antipsychotics. However, whether individual atypical and typical antipsychotics are associated with differential AKI risks has not been investigated. OBJECTIVE:The current study compared the risks of...

journal_title：CNS drugs

authors： Jiang Y,McCombs JS,Park SH

更新日期：2017-04-01 00:00:00

abstract：:Cytomegalovirus (CMV) infection of the CNS occurs most commonly in patients with severe immunosuppression such as those with advanced HIV infection (i.e. AIDS) or those who have undergone bone marrow or solid organ transplantation. Immunocompetent patients are affected very rarely. The infection of the CNS may affect ...

journal_title：CNS drugs

authors： Maschke M,Kastrup O,Diener HC

更新日期：2002-01-01 00:00:00

abstract：:Biopharmaceuticals can induce antibodies, which interact with and neutralize the therapeutic effect of such drugs and are therefore termed neutralizing antibodies (NAbs). In the treatment of multiple sclerosis, NAbs against interferon (IFN)-beta and natalizumab have been recognized. The prevalence of NAbs against diff...

journal_title：CNS drugs

authors： Deisenhammer F

更新日期：2009-01-01 00:00:00

abstract：:Glutamatergic, noradrenergic, serotonergic, and cholinergic systems play a critical role in the basal ganglia circuitry. Targeting these non-dopaminergic receptors remains a focus of ongoing research to improve Parkinson's disease (PD) motor symptoms, without the potential side effects of dopamine replacement therapy....

journal_title：CNS drugs

authors： Gonzalez-Latapi P,Bhowmick SS,Saranza G,Fox SH

更新日期：2020-10-01 00:00:00

abstract：:Disability, characterised by the loss of ability to perform activities of daily living (ADL), is a defining feature of dementia that results in growing caregiver burden and the eventual need for alternative care or nursing home placement. Functional decline in patients with dementia can also result from causes other t...

journal_title：CNS drugs

authors： Desai AK,Grossberg GT,Sheth DN

更新日期：2004-01-01 00:00:00

abstract：:Spinal cord injury (SCI) has a number of severe and disabling consequences, including chronic pain, and around 40% of patients develop persistent neuropathic pain. Pain following SCI has a detrimental impact on the patient's quality of life and is a major specific healthcare problem in its own right. Thus far, there i...

journal_title：CNS drugs

authors： Baastrup C,Finnerup NB

更新日期：2008-01-01 00:00:00

abstract：:Friedreich ataxia (FA) is a progressive genetic neurological disorder associated with degeneration of the dorsal columns, spinocerebellar tracts and other regions of the nervous system. The disorder results from mutations in the gene referred to as FXN. Almost all mutations are expansions of an intronic GAA repeat in ...

journal_title：CNS drugs

authors： Tsou AY,Friedman LS,Wilson RB,Lynch DR

更新日期：2009-01-01 00:00:00

abstract：OBJECTIVE:To collect descriptive data on the treatment of Alzheimer's disease with galantamine under naturalistic conditions. STUDY DESIGN:This was a prospective, open-label, observational study. PATIENTS:Subjects (n = 345) with mild to moderately severe dementia of the Alzheimer's type were recruited from 48 hospita...

journal_title：CNS drugs

authors： Brodaty H,Woodward M,Boundy K,Barnes N,Allen G,NATURE Investigators.

更新日期：2006-01-01 00:00:00

abstract：:New formulations of stimulant medications for the treatment of attention-deficit hyperactivity disorder (ADHD) have been an important focus for pharmaceutical industry research and development over the past decade. In this article, we review and assess the therapeutic potential of five new stimulant formulations (one ...

journal_title：CNS drugs

authors： Connor DF,Steingard RJ

更新日期：2004-01-01 00:00:00

abstract：:Oral blonanserin (Lonasen) is an atypical antipsychotic agent indicated for use in patients with schizophrenia in Japan and Korea. It is effective in the treatment of patients with schizophrenia, providing short- and long-term efficacy against both the positive and negative symptoms of the disorder in several randomiz...

journal_title：CNS drugs

authors： Deeks ED,Keating GM

更新日期：2010-01-01 00:00:00

abstract：INTRODUCTION:Cognitive impairment is prevalent and debilitating among persons with multiple sclerosis (MS). While many pharmacologic treatments have shown good efficacy in reducing clinical relapses, brain lesions, and improving certain physical symptoms, their efficacy for improving cognitive function is not well unde...

journal_title：CNS drugs

authors： Chen MH,Goverover Y,Genova HM,DeLuca J

更新日期：2020-06-01 00:00:00

abstract：:All antipsychotics, including the atypical antipsychotics (AAPs), may cause tardive dyskinesia (TD), a potentially irreversible movement disorder, the pathophysiology of which is currently unknown. The prevention and treatment of TD remain major challenges for clinicians. We conducted a PubMed search to review the pre...

journal_title：CNS drugs

authors： Stegmayer K,Walther S,van Harten P

更新日期：2018-02-01 00:00:00

abstract：BACKGROUND:Walking impairment is a hallmark of multiple sclerosis (MS). It affects > 90% of individuals over time, reducing independence and negatively impacting health-related quality of life, productivity, and daily activities. Walking impairment is consistently reported as one of the most distressing impairments by ...

journal_title：CNS drugs

authors： Hobart J,Ziemssen T,Feys P,Linnebank M,Goodman AD,Farrell R,Hupperts R,Blight AR,Englishby V,McNeill M,Chang I,Lima G,Elkins J,ENHANCE study investigators.

更新日期：2019-01-01 00:00:00

abstract：BACKGROUND:Diroximel fumarate (DRF) is a novel oral fumarate approved in the USA for relapsing forms of multiple sclerosis. DRF is converted to monomethyl fumarate, the pharmacologically active metabolite of dimethyl fumarate (DMF). DRF 462 mg and DMF 240 mg produce bioequivalent exposure of monomethyl fumarate and are...

journal_title：CNS drugs

authors： Naismith RT,Wundes A,Ziemssen T,Jasinska E,Freedman MS,Lembo AJ,Selmaj K,Bidollari I,Chen H,Hanna J,Leigh-Pemberton R,Lopez-Bresnahan M,Lyons J,Miller C,Rezendes D,Wolinsky JS,EVOLVE-MS-2 Study Group.

更新日期：2020-02-01 00:00:00

abstract：:The basal ganglia and dopaminergic pathways play a central role in hyperkinetic movement disorders. Vesicular monoamine transporter 2 (VMAT2) inhibitors, which deplete dopamine at presynaptic striatal nerve terminals, are a class of drugs that have long been used to treat hyperkinetic movement disorders, but have rece...

journal_title：CNS drugs

authors： Tarakad A,Jimenez-Shahed J

更新日期：2018-12-01 00:00:00

abstract：:Despite the established efficacy of chimeric antigen receptor (CAR) T-cell therapy in hematologic malignancies, translating CAR T therapy to solid tumors has remained investigational. Glioblastoma, the most aggressive and lethal form of primary brain tumor, has recently been among the malignancies being trialed clinic...

journal_title：CNS drugs

authors： Salinas RD,Durgin JS,O'Rourke DM

更新日期：2020-02-01 00:00:00

abstract：:In this article, we review the evidence that tocopherol (vitamin E) may have a role to play in the prevention and treatment of Alzheimer's disease and other neurological diseases. The theoretical rationale for the effectiveness of tocopherol as treatment and/or prevention of Alzheimer's disease is based on its antioxi...

journal_title：CNS drugs

authors： Berman K,Brodaty H

更新日期：2004-01-01 00:00:00

abstract：:This article reviews the conceptual progression in the pharmacological therapy of malignant astrocytoma (MA) over the past decade, and its future trends. It is a selective rather than an exhaustive inventory of literature citations. The experience of the Brain Tumour Cooperative Group (BTCG) and earlier phase III tria...

journal_title：CNS drugs

authors： Jennings MT,Iyengar S

更新日期：2001-01-01 00:00:00

abstract：:Satisfactory management of Parkinson's disease is a challenge that requires a tailored approach for each individual. In the advanced phase of the disease, patients may experience motor complications despite optimized pharmacological therapy. Apomorphine, a short-acting D1- and D2-like receptor agonist, is the only dru...

journal_title：CNS drugs

authors： Carbone F,Djamshidian A,Seppi K,Poewe W

更新日期：2019-09-01 00:00:00

abstract：:Treatment-resistant depression (TRD) presents major challenges for both patients and clinicians. There is no universally accepted definition of TRD, but results from the US National Institute of Mental Health's (NIMH) STAR*D (Sequenced Treatment Alternatives to Relieve Depression) programme indicate that after the fai...

journal_title：CNS drugs

authors： Shelton RC,Osuntokun O,Heinloth AN,Corya SA

更新日期：2010-02-01 00:00:00

abstract：:The pervasive and devastating nature of substance use disorders underlies the need for the continued development of novel pharmacotherapies. We now know that glia play a much greater role in neuronal processes than once believed.  The various types of glial cells (e.g., astrocytes, microglial, oligodendrocytes) partic...

journal_title：CNS drugs

authors： Jones JD

更新日期：2020-07-01 00:00:00